AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23318127 — intervention group
Group type: COMPARATOR
Intervention: DD
Number of subjects: 191
Study 23318127 — intervention group
Group type: EXPERIMENTAL
Intervention: ET
Number of subjects: 191
Study 19850640 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intensity doxorubicin-based regimens
Number of subjects: 8
Study 19850640 — intervention group
Group type: COMPARATOR
Intervention: CHOP (control arm)
Number of subjects: 8
Study 18226670 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA 150 mg intramuscularly
Number of subjects: 70
Study 17238814 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac tromethamine 0.5%
Number of subjects: 30
Study 17238814 — intervention group
Group type: COMPARATOR
Intervention: Artificial tear drop (placebo)
Number of subjects: 30
Study 12571480 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest reconstruction using MacroPore sheet and Inductive Conductive Matrix (ICM)
Number of subjects: 46
Study 12571480 — intervention group
Group type: COMPARATOR
Intervention: No donor site reconstruction
Number of subjects: 46
Study 12571480 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest reconstruction
Number of subjects: 46
Study 11004040 — intervention group
Group type: COMPARATOR
Intervention: Diprivan(TM)
Number of subjects: 200
Study 11004040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisulfite-containing propofol 1.5 mg/kg IV
Number of subjects: 200
Study 8823692 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac, 100 mg bid orally
Number of subjects: 273
Study 8823692 — intervention group
Group type: COMPARATOR
Intervention: Tenoxicam, 20 mg orally at bedtime
Number of subjects: 273
Study 8823692 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Number of subjects: 273
Study 8823692 — intervention group
Group type: COMPARATOR
Intervention: Tenoxicam
Number of subjects: 273
Study 1349496 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg daily for 7 days
Number of subjects: 16
Study 3512461 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% malathion lotion
Number of subjects: 119
Study 3512461 — intervention group
Group type: COMPARATOR
Intervention: Control lotion (vehicle)
Number of subjects: 119
Study 31879229 — intervention group
Group type: EXPERIMENTAL
Intervention: Incubation for 90 min (group A)
Number of subjects: 100
Study 31879229 — intervention group
Group type: EXPERIMENTAL
Intervention: Incubation for 180 min (group B)
Number of subjects: 100
Study 29558782 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum (Monapax syrup)
Number of subjects: 180
Study 29558782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 27382456 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (70 mg) administered at three hours and 24 hours after pregnancy termination
Number of subjects: 60
Study 27382456 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at three hours and 24 hours after pregnancy termination
Number of subjects: 60
Study 24802951 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500 mg · day(‐1))
Number of subjects: 31
Study 24802951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 22526068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream containing green tea extract
Number of subjects: 10
Study 16125495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0
Study 12130401 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions in subjects with patellofemoral pain
Number of subjects: 0
Study 12130401 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 9569477 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B virus (HBV) vaccines administered at 2, 4, and 12 months of age, concurrent with OPV and DTP vaccination.
Number of subjects: 1237
Study 9569477 — intervention group
Group type: COMPARATOR
Intervention: Whole cell DTP and three-component acellular DTaPs administered as part of the vaccination schedule.
Number of subjects: 1237
Study 9569477 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody response measured by ELISA for HBsAg.
Number of subjects: 1237
Study 7978174 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ventilation with Kuhn's T‐piece system and face mask (group A; n = 11)
Number of subjects: 42
Study 7978174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with paediatric circle system, endotracheal tube, and positive end‐expiratory pressure (PEEP) 3 cm H2O (group D; n = 10)
Number of subjects: 42
Study 7978174 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ventilation with paediatric circuit system and face mask (group C; n = 11)
Number of subjects: 42
Study 7978174 — intervention group
Group type: COMPARATOR
Intervention: Manual ventilation with endotracheal tube (group B; n = 10)
Number of subjects: 42
Study 2729632 — intervention group
Group type: EXPERIMENTAL
Intervention: Single breath test (Crssb)
Number of subjects: 18
Study 2729632 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume recruitment maneuver (Crsvr)
Number of subjects: 18
Study 1218170 — intervention group
Group type: EXPERIMENTAL
Intervention: etidocaine
Number of subjects: 100
Study 1218170 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine
Number of subjects: 100
Study 12471569 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-atovaquone-proguanil
Number of subjects: 1596
Study 12471569 — intervention group
Group type: COMPARATOR
Intervention: artesunate-mefloquine
Number of subjects: 1596
Study 12471569 — intervention group
Group type: COMPARATOR
Intervention: atovaquone-proguanil-artesunate
Number of subjects: 1596
Study 12471569 — intervention group
Group type: COMPARATOR
Intervention: atovaquone-proguanil
Number of subjects: 1596
Study 12471569 — intervention group
Group type: COMPARATOR
Intervention: artesunate
Number of subjects: 1596
Study 12471569 — intervention group
Group type: COMPARATOR
Intervention: mefloquine
Number of subjects: 1596
Study 30661700 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A treatment (100,000 IU intramuscular daily for 7 days)
Number of subjects: 63
Study 30661700 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (blinded placebo daily for 7 days)
Number of subjects: 63
Study 29353426 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone (1 g) administered preemptively before surgery
Number of subjects: 25
Study 29353426 — intervention group
Group type: COMPARATOR
Intervention: Dipyrone (1 g) administered in the immediate postoperative period
Number of subjects: 25
Study 27898166 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (7- to 14-day regimen with PPI, clarithromycin, and either amoxicillin or an imidazole)
Number of subjects: 257
Study 27898166 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (5 days of PPI and amoxicillin followed by 5 days of PPI, clarithromycin, and an imidazole)
Number of subjects: 257
Study 27898166 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day sequential therapy (5 days of PPI and amoxicillin followed by 5 days of PPI, clarithromycin, and an imidazole)
Number of subjects: 257
Study 24055350 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of Q-HPV vaccine at 0, 6 months (n=259)
Number of subjects: 824
Study 24055350 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of Q-HPV vaccine at 0, 2, 6 months (n=260)
Number of subjects: 824
Study 24055350 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of Q-HPV vaccine at 0, 2, 6 months (n=305)
Number of subjects: 824
Study 24055350 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of Q-HPV vaccine (all subjects)
Number of subjects: 824
Study 24055350 — intervention group
Group type: EXPERIMENTAL
Intervention: PsV NAb assay
Number of subjects: 824
Study 23327034 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microg/kg (group D)
Number of subjects: 40
Study 23327034 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (group P)
Number of subjects: 40
Study 19656221 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day
Number of subjects: 30
Study 19656221 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 30
Study 18806966 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg SF‐TRE
Number of subjects: 36
Study 18806966 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg SF‐TRE
Number of subjects: 36
Study 18806966 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg SF‐TRE
Number of subjects: 36
Study 18806966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16297562 — intervention group
Group type: EXPERIMENTAL
Intervention: Current illicit drug use (N=253)
Number of subjects: 2267
Study 16297562 — intervention group
Group type: EXPERIMENTAL
Intervention: Past drug use (N=617)
Number of subjects: 2267
Study 16297562 — intervention group
Group type: COMPARATOR
Intervention: Non-users (N=1397)
Number of subjects: 2267
Study 16297562 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (age, sex, SES)
Number of subjects: 2267
Study 16297562 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior pain
Number of subjects: 2267
Study 16297562 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS illness burden
Number of subjects: 2267
Study 16297562 — intervention group
Group type: EXPERIMENTAL
Intervention: Current substance use at baseline
Number of subjects: 2267
Study 16297562 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous illness burden
Number of subjects: 2267
Study 12087523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal virosomal influenza vaccine
Number of subjects: 133
Study 12087523 — intervention group
Group type: COMPARATOR
Intervention: No vaccination (control)
Number of subjects: 133
Study 9459315 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic DVT
Number of subjects: 264
Study 9459315 — intervention group
Group type: COMPARATOR
Intervention: Secondary DVT
Number of subjects: 264
Study 9459315 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent venous thromboembolism
Number of subjects: 264
Study 9459315 — intervention group
Group type: COMPARATOR
Intervention: Without recurrent venous thromboembolism
Number of subjects: 264
Study 7707846 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser irradiation (lambda = 308 nm, pulsewidth: 20 ns, repetition rate: 10‐70 Hz, radiant exposure: 10‐50 mJ/mm2)
Number of subjects: 0
Study 7707846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (lambda = 1064 nm, energy density: 21‐93 W/mm2)
Number of subjects: 0
Study 7707846 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonirradiated menisci)
Number of subjects: 0
Study 7707846 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser meniscectomy (both excimer and Nd:YAG)
Number of subjects: 0
Study 2675931 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Learning (CAL) program
Number of subjects: 0
Study 2675931 — intervention group
Group type: COMPARATOR
Intervention: Lecture method
Number of subjects: 0
Study 551921 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific hypotensive therapy (Ht)
Number of subjects: 0
Study 551921 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated hypertensive group (Hu)
Number of subjects: 0
Study 551921 — intervention group
Group type: COMPARATOR
Intervention: Hospital sample (S)
Number of subjects: 0
Study 31628576 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-axis rotational coronary angiography (DARCA)
Number of subjects: 70
Study 31628576 — intervention group
Group type: COMPARATOR
Intervention: Standard coronary angiography (SA)
Number of subjects: 70
Study 30707692 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 334968
Study 28039022 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2mA current for 20min/session over 10 sessions)
Number of subjects: 84
Study 28039022 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (control group)
Number of subjects: 84
Study 25479182 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient palliative care consult with follow-up as determined by provider
Number of subjects: 232
Study 25479182 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 232
Study 23218453 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondhand smoke exposure for 1 hour
Number of subjects: 18
Study 22335953 — intervention group
Group type: EXPERIMENTAL
Intervention: TC combined with endostar
Number of subjects: 126
Study 22335953 — intervention group
Group type: COMPARATOR
Intervention: TC (control)
Number of subjects: 126
Study 19371483 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (expect alcohol/receive alcohol)
Number of subjects: 91
Study 19371483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (expect alcohol/receive placebo)
Number of subjects: 91
Study 19371483 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol control (expect no alcohol/receive no alcohol)
Number of subjects: 91
Study 16870035 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable bipolar diathermy
Number of subjects: 168
Study 16870035 — intervention group
Group type: COMPARATOR
Intervention: Reusable monopolar diathermy
Number of subjects: 168
Study 15099173 — intervention group
Group type: EXPERIMENTAL
Intervention: PAN intervention (physical activity and nutrition)
Number of subjects: 138
Study 15099173 — intervention group
Group type: EXPERIMENTAL
Intervention: PA intervention (physical activity alone)
Number of subjects: 138
Study 15099173 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 138
Study 11544618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Saver (CS) blood salvage during CABG surgery
Number of subjects: 45
Study 9230648 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot (3.75 mg once a month for 3 months)
Number of subjects: 33
Study 9230648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 7965538 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency oscillation at 10 Hz
Number of subjects: 12
Study 7965538 — intervention group
Group type: COMPARATOR
Intervention: High frequency oscillation at 15 Hz
Number of subjects: 12
Study 3677283 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine, 0.04 mg.kg‐1
Number of subjects: 120
Study 3677283 — intervention group
Group type: COMPARATOR
Intervention: Pyridostigmine, 0.2 mg.kg‐1
Number of subjects: 120
Study 3677283 — intervention group
Group type: COMPARATOR
Intervention: Edrophonium, 0.54 mg.kg‐1
Number of subjects: 120
Study 29198157 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol valerate daily plus 4 mg medroxyprogesterone acetate on days 19–30
Number of subjects: 96
Study 29198157 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol valerate daily plus 100 mg micronized progesterone on days 19–30
Number of subjects: 96
Study 29198157 — intervention group
Group type: COMPARATOR
Intervention: 100 mg C. foetida extract daily
Number of subjects: 96
Study 27716201 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care CRP testing in all children (1730 episodes)
Number of subjects: 3147
Study 27716201 — intervention group
Group type: COMPARATOR
Intervention: Restricted CRP testing to children identified as at clinical risk (1417 episodes)
Number of subjects: 3147
Study 27716201 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP < 5 mg/L
Number of subjects: 3147
Study 27716201 — intervention group
Group type: EXPERIMENTAL
Intervention: Children referred to hospital to rule out serious infection (80 children)
Number of subjects: 3147
Study 23229841 — intervention group
Group type: EXPERIMENTAL
Intervention: Think Again advertisement
Number of subjects: 102
Study 22520298 — intervention group
Group type: EXPERIMENTAL
Intervention: Winners with high baseline testosterone and low baseline cortisol
Number of subjects: 0
Study 22520298 — intervention group
Group type: COMPARATOR
Intervention: Losers
Number of subjects: 0
Study 21412011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology institute of campus II
Number of subjects: 700
Study 21412011 — intervention group
Group type: COMPARATOR
Intervention: Pathology institute of campus I
Number of subjects: 700
Study 18031594 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bisphosphonates (alendronate, risedronate, ibandronate)
Number of subjects: 0
Study 18031594 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (administered with an extended between-dose interval)
Number of subjects: 0
Study 18031594 — intervention group
Group type: COMPARATOR
Intervention: Non-daily oral bisphosphonates
Number of subjects: 0
Study 15731977 — intervention group
Group type: EXPERIMENTAL
Intervention: Information group (oral and written information about baby blues and postpartum depression)
Number of subjects: 169
Study 15731977 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information provided)
Number of subjects: 169
Study 15731977 — intervention group
Group type: EXPERIMENTAL
Intervention: Information group (EPDS scores)
Number of subjects: 169
Study 15731977 — intervention group
Group type: COMPARATOR
Intervention: Control group (EPDS scores)
Number of subjects: 169
Study 15731977 — intervention group
Group type: EXPERIMENTAL
Intervention: Information group (self-evaluation of depression)
Number of subjects: 169
Study 15731977 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-evaluation of depression)
Number of subjects: 169
Study 12532113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary omega-3 fatty acids supplementation
Number of subjects: 616
Study 12532113 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM avoidance intervention
Number of subjects: 616
Study 10229740 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (10 mg/d IV) over 2 hours for 7 days
Number of subjects: 17
Study 10229740 — intervention group
Group type: COMPARATOR
Intervention: None (no CVD group)
Number of subjects: 17
Study 9367941 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug formulation containing dimethylaminoethanolorotrate (DMAE), vitamins and minerals, 1 capsule per day for 12 weeks
Number of subjects: 60
Study 9367941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1758745 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment
Number of subjects: 19
Study 1758745 — intervention group
Group type: COMPARATOR
Intervention: Control group not receiving theophylline
Number of subjects: 19
Study 1758745 — intervention group
Group type: COMPARATOR
Intervention: Nonasthmatic control group
Number of subjects: 19
Study 6127349 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta-blocker)
Number of subjects: 4200
Study 6127349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4200
Study 30620370 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-payment vouchers for clopidogrel or ticagrelor for 1 year (n=6436 patients)
Number of subjects: 11001
Study 30620370 — intervention group
Group type: COMPARATOR
Intervention: Usual care without vouchers (n=4565 patients)
Number of subjects: 11001
Study 29177980 — intervention group
Group type: EXPERIMENTAL
Intervention: LED irradiation (LEDI) on ipsilateral limb
Number of subjects: 12
Study 29177980 — intervention group
Group type: COMPARATOR
Intervention: Placebo on ipsilateral limb
Number of subjects: 12
Study 29177980 — intervention group
Group type: EXPERIMENTAL
Intervention: LED irradiation (LEDI) on contralateral limb
Number of subjects: 12
Study 29177980 — intervention group
Group type: COMPARATOR
Intervention: Placebo on contralateral limb
Number of subjects: 12
Study 27005901 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphasia Action Success Knowledge Program
Number of subjects: 344
Study 27005901 — intervention group
Group type: COMPARATOR
Intervention: Secondary Stroke Prevention Information Program
Number of subjects: 344
Study 24768717 — intervention group
Group type: EXPERIMENTAL
Intervention: Hara‐Hachibu condition
Number of subjects: 11
Study 24768717 — intervention group
Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 11
Study 22491810 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 weeks of small-group, Tier 2 intervention
Number of subjects: 129
Study 22491810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tier 1 data
Number of subjects: 129
Study 22491810 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models
Number of subjects: 129
Study 19409854 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (200 mg)
Number of subjects: 130
Study 19409854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 17632309 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 80
Study 17632309 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 80
Study 15693467 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with massage
Number of subjects: 80
Study 15693467 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with verbal coaching and slow breathing
Number of subjects: 80
Study 15693467 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with massage and verbal coaching and slow breathing combined
Number of subjects: 80
Study 15693467 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 11486930 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit learning of sequences (length 8)
Number of subjects: 0
Study 11486930 — intervention group
Group type: COMPARATOR
Intervention: External precues introduced in a 3rd experiment
Number of subjects: 0
Study 9754457 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network model for predicting heparin concentrations
Number of subjects: 119
Study 9754457 — intervention group
Group type: COMPARATOR
Intervention: NONMEM model for predicting heparin concentrations
Number of subjects: 119
Study 9754457 — intervention group
Group type: EXPERIMENTAL
Intervention: Final NONMEM model using all data
Number of subjects: 119
Study 9754457 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of distribution and clearance
Number of subjects: 119
Study 9754457 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of distribution
Number of subjects: 119
Study 8144738 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric Toothbrush (ET)
Number of subjects: 40
Study 8144738 — intervention group
Group type: COMPARATOR
Intervention: Manual Toothbrush (MT)
Number of subjects: 40